Showing 3931-3940 of 5771 results for "".
- Neurolens Wins Inaugural KMK Optometry Vision Innovation (KOVI) Awardhttps://modernod.com/news/neurolens-wins-inaugural-kmk-optometry-vision-innovation-kovi-award/2480494/Neurolens has been announced as the winner of the inaugural KMK Optometry Vision Innovation (KOVI) Award.
- Amydis Has Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALShttps://modernod.com/news/amydis-has-pre-ind-meeting-with-the-fda-for-the-development-of-a-first-in-class-retinal-tracer-targeting-tdp43-for-the-diagnosis-of-als/2480493/Amydis announced the successful completion of a pre-IND (investigational new drug) meeting with the FDA regarding the development plans for a small-molecule tracer to detect TDP43 in the retina of amyotrophic lateral sclerosis (ALS) patients. The FDA agreed with the overall d
- Omeros to Sell Omidria Franchise to Rayner in a Deal Worth More Than $1 Billionhttps://modernod.com/news/omeros-to-sell-omidria-franchise-to-rayner-in-a-deal-worth-more-than-1-billion/2480488/Omeros announced that it has entered into a definitive agreement for the sale of Omidria to Rayner Surgical Group. The transaction, which is expected to close on or before December 31, 2021, includes an upfront payment of $125 million with an additional $200 million in
- LayerBio Granted U.S. Patent for OcuRing Drug Delivery Platformhttps://modernod.com/news/layerbio-granted-us-patent-for-ocuring-drug-delivery-platform/2480486/LayerBio announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,185,441. "This patent issuance marks an important milestone for the OcuRing platform and recognition of novelty and uniqueness of our drug delivery technology,&
- Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directorshttps://modernod.com/news/alimera-sciences-welcomes-ophthalmic-strategic-consultant-erin-parsons-to-its-board-of-directors/2480483/Alimera Sciences announced the addition of Erin Parsons to its Board of Directors. Ms. Parsons has more than 20 years of experience working in the ophthalmic industry overseeing scientific strategy, medical communications, advocacy development, and peer-to-peer educational programs, muc
- Nicox’s Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path Forward in Dry Eye Diseasehttps://modernod.com/news/nicoxs-positive-post-hoc-results-from-ncx-4251-phase-2b-mississippi-trial-suggest-path-forward-in-dry-eye-disease/2480480/Nicox SA announced positive post hoc results from its Mississippi Phase 2b clinical trial suggesting that once-daily dosed NCX 4251, fluticasone propionate ophth
- Inspecs Acquires Hardy Amies Brandhttps://modernod.com/news/inspecs-acquires-hardy-amies-brand/2480476/Inspecs, a designer, manufacturer and distributor of eyewear frames and lenses, has announced the acquisition of the Hardy Amies brand, including all global intellectual property rights. Terms of the deal were not disclosed. Hardy Amies was founded by Sir Hardy Amie
- Oyster Point Pharma Expands Executive Leadership Team to Support Commercialization of Tyrvaya Nasal Sprayhttps://modernod.com/news/oyster-point-pharma-announces-expansion-of-executive-leadership-team-to-support-commercialization-of-tyrvaya-nasal-spray/2480475/Oyster Point Pharma announced the promotion of Barry Rosenfeld, JD, as General Counsel; and Raegan A. McClain, JD, LLM, CCEP, as Chief Compliance Officer, both of whom will join the executive leadership team. “We are thrilled to expand our executive
- IOLCon Designed to Map Out the Road for Reliable IOL Calculationhttps://modernod.com/news/iolcon-is-mapping-out-the-road-for-reliable-iol-calculation/2480474/Internet database IOLCon announced updates to its website,
- Microinvasive Glaucoma Surgery with the OMNI Surgical System is Associated with Diminished Diurnal IOP Fluctuationshttps://modernod.com/news/microinvasive-glaucoma-surgery-with-the-omni-surgical-system-is-associated-with-diminished-diurnal-iop-fluctuations/2480463/Sight Sciences announced publication in